Merck & Co (MRK)
86.40
+0.00 (0.00%)
NYSE · Last Trade: Oct 9th, 8:37 AM EDT
After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.
Via MarketBeat · October 9, 2025
Merck and health experts push back against U.S. officials' call to split the MMR vaccine, warning it could delay immunizations and weaken immune response.
Via Benzinga · October 7, 2025
Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug.
Via Investor's Business Daily · October 7, 2025
This biotech company was relatively unknown a few years ago.
Via The Motley Fool · October 5, 2025
S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easing and AI tech.
Via Benzinga · October 3, 2025
Via Benzinga · October 3, 2025
Washington D.C., October 2, 2025 – As a federal government shutdown extends into its second day, the highly anticipated U.S. Jobs Report, typically released on the first Friday of each month, has been delayed indefinitely. This immediate consequence of the government's funding lapse creates a significant blind spot for
Via MarketMinute · October 2, 2025
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.
Via Benzinga · October 2, 2025
Worried about sliding interest on your savings? These three Dow stocks are yielding more than 4%.
Via The Motley Fool · October 2, 2025
Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a Phase 1 study of its lead product, JNJ-1900 (NBTXR3), in patients with locally advanced esophageal adenocarcinoma. This pivotal development, revealed
Via MarketMinute · October 2, 2025
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented ability to design synthetic proteins for genome editing that not only match but significantly outperform their naturally occurring counterparts. This pivotal development, highlighted by recent research, signals a [...]
Via TokenRing AI · October 2, 2025
Stocks shrugged off Washington’s chaos as hopes for Fed rate cuts and strong corporate news kept investors in a buying mood.
Via Chartmill · October 2, 2025
Shares of global pharmaceutical company Merck (NYSE:MRK)
jumped 7.7% in the afternoon session after the Trump administration announced a new program to sell drugs directly to consumers.
Via StockStory · October 1, 2025
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tariffs.
Via Benzinga · October 1, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
Via Chartmill · October 1, 2025
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.
Via Chartmill · October 1, 2025
Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat.
Via Benzinga · October 1, 2025
As the third quarter of 2025 drew to a close on September 30, global financial markets demonstrated a remarkable display of resilience, largely shrugging off significant geopolitical uncertainties and the imminent threat of a U.S. federal government shutdown. Major U.S. indices, including the Dow Jones Industrial Average (NYSE:
Via MarketMinute · September 30, 2025
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
Via MarketMinute · September 30, 2025
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing agreement reached between the White House and a major pharmaceutical player, Pfizer (NYSE: PFE). This development has been widely interpreted by investors as
Via MarketMinute · September 30, 2025
Shares of global pharmaceutical company Merck (NYSE:MRK)
jumped 5.7% in the afternoon session after the company announced positive results from its Phase 3 HYPERION trial for its drug, WINREVAIR™ (sotatercept-csrk).
Via StockStory · September 30, 2025
The global cattle feeding industry is at a critical juncture, facing mounting pressures from volatile feed costs, stringent environmental regulations, and a persistent labor crunch. In response, a wave of innovative technologies is rapidly transforming traditional practices, promising enhanced efficiency, sustainability, and profitability. This technological pivot, driven by advancements in
Via MarketMinute · September 30, 2025
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · September 30, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · September 30, 2025
Merck reported Phase 3 results showing Winrevair significantly reduced clinical worsening in pulmonary arterial hypertension patients.
Via Benzinga · September 30, 2025